-
Mashup Score: 0Inflammasome Therapeutics doses first patient in Phase 1 trial of Kamuvudine-8 for geographic atrophy - 10 hour(s) ago
Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 2Deep learning model for AI: Stopping nascent GA in its tracks - 17 hour(s) ago
Researchers found the model demonstrated “near-perfect” detection capabilities.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 3Claris Bio's journey toward treating neurotrophic keratitis - 21 hour(s) ago
David Hutton, Managing Editor of Ophthalmology Times sat down with Claris Bio CEO, Clarke Atwell, to discuss the company’s path toward developing treatment for neurotrophic keratitis.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 0Study: Pediatric eye care deserts are a growing issue - 1 day(s) ago
Researchers examined disparities in service coverage of pediatric ophthalmologists and pediatric optometrists in relation to patient demographics to cast a light on at-risk populations and provide data for future decisions.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Pediatric eye care deserts are a growing issue. Researchers examined disparities in coverage of pediatric ophthalmologists and optometrists compared to patient demographics to cast light on at-risk populations and gain data for future decisions Read More: https://t.co/a3AbEWEjOP https://t.co/TRJJkTDk4b
-
-
Mashup Score: 7
The data will be presented in oral session at the 2024 American Society of Gene & Cell Therapy meeting May 7-11 in Baltimore, Maryland.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 19Interactive online tool, Vision Simulator, highlights vision loss caused by retinal diseases - 2 day(s) ago
The tool shows disease progression and vision loss simulations for multiple diseases such as AMD, XLRP, and achromatopsia
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 9ASCRS 2024: An update from ViaLase on its technology for a nonincisional approach to treating glaucoma. - 2 day(s) ago
Rick Lewis, chief medical officer of ViaLase, describes the company’s nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 2
Researchers found the model demonstrated “near-perfect” detection capabilities.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 5Sean Donahue, MD, PhD, to become president of the American Association for Pediatric Ophthalmology and Strabismus - 2 day(s) ago
Donahue will serve as president until June 30, 2025, when he will host the AAPOS 2025 annual meeting in Salt Lake City, Utah. He previously had served as vice president since July 2023.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 0Study: Pediatric eye care deserts are a growing issue - 2 day(s) ago
Researchers examined disparities in service coverage of pediatric ophthalmologists and pediatric optometrists in relation to patient demographics to cast a light on at-risk populations and provide data for future decisions.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Pediatric eye care deserts are a growing issue. Researchers examined disparities in coverage of pediatric ophthalmologists and optometrists compared to patient demographics to cast light on at-risk populations and gain data for future decisions Read More: https://t.co/a3AbEWEjOP https://t.co/TRJJkTDk4b
-
Inflammasome Therapeutics has dosed the first patient in its Phase 1 clinical trial evaluating Kamuvudine-8 in subjects with geographic atrophy (GA). K8 is administered to the back of the eye via a sustained released intravitreal implant. Read More: https://t.co/HL4Sgc9vtw https://t.co/nBHURKziDL